184 related articles for article (PubMed ID: 24392977)
1. Reliably basing conclusions on subgroups of randomized clinical trials.
Koch A; Framke T
J Biopharm Stat; 2014; 24(1):42-57. PubMed ID: 24392977
[TBL] [Abstract][Full Text] [Related]
2. Design and evaluation of multiregional trials with heterogeneous treatment effect across regions.
Chen CT; Hung HM; Hsiao CF
J Biopharm Stat; 2012 Sep; 22(5):1037-50. PubMed ID: 22946948
[TBL] [Abstract][Full Text] [Related]
3. An urn model for odds-ratio-based response-adaptive phase III clinical trials for two or more treatments.
Basak GK; Biswas A; Volkov S
J Biopharm Stat; 2009 Sep; 19(5):838-56. PubMed ID: 20183447
[TBL] [Abstract][Full Text] [Related]
4. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2012 Jun; 73(6):856-64. PubMed ID: 22687813
[TBL] [Abstract][Full Text] [Related]
5. Statistical principles: myths or facts?
Sylvester R
Onkologie; 2003 Dec; 26(6):520-1. PubMed ID: 14709923
[No Abstract] [Full Text] [Related]
6. Randomized clinical trial: myths around elementary statistical principles.
Edler L; Kopp-Schneider A
Onkologie; 2003 Dec; 26(6):551-6. PubMed ID: 14709929
[TBL] [Abstract][Full Text] [Related]
7. An overview of statistical and regulatory issues in the planning, analysis, and interpretation of subgroup analyses in confirmatory clinical trials.
Hemmings R
J Biopharm Stat; 2014; 24(1):4-18. PubMed ID: 24392975
[TBL] [Abstract][Full Text] [Related]
8. Confirmatory clinical trials with an adaptive design.
Koch A
Biom J; 2006 Aug; 48(4):574-85. PubMed ID: 16972708
[TBL] [Abstract][Full Text] [Related]
9. Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading?
Hernández AV; Boersma E; Murray GD; Habbema JD; Steyerberg EW
Am Heart J; 2006 Feb; 151(2):257-64. PubMed ID: 16442886
[TBL] [Abstract][Full Text] [Related]
10. An overview of statistical planning to address subgroups in confirmatory clinical trials.
Koch GG; Schwartz TA
J Biopharm Stat; 2014; 24(1):72-93. PubMed ID: 24392979
[TBL] [Abstract][Full Text] [Related]
11. [Introduction to the statistical aspects of planning clinical oncologic phase III studies].
Sylvester R; Minder CE
Urologe A; 1995 Sep; 34(5):367-73. PubMed ID: 7483152
[TBL] [Abstract][Full Text] [Related]
12. A flexible design for multiple armed screening trials.
Sargent DJ; Goldberg RM
Stat Med; 2001 Apr; 20(7):1051-60. PubMed ID: 11276035
[TBL] [Abstract][Full Text] [Related]
13. How practical are adaptive designs likely to be for confirmatory trials?
Gould AL
Biom J; 2006 Aug; 48(4):644-9; discussion 660-2. PubMed ID: 16972716
[TBL] [Abstract][Full Text] [Related]
14. The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent.
Serebruany VL
Cardiology; 2011; 120(3):169-71. PubMed ID: 22418766
[TBL] [Abstract][Full Text] [Related]
15. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
16. Applying sensitivity analyses to overall survival in cancer clinical trials.
Wolff SN
J Clin Oncol; 2010 Jul; 28(19):e323; author reply e324. PubMed ID: 20516448
[No Abstract] [Full Text] [Related]
17. Subgroup Analyses in Reporting of Phase III Clinical Trials in Solid Tumors.
Zhang S; Liang F; Li W; Hu X
J Clin Oncol; 2015 May; 33(15):1697-702. PubMed ID: 25897150
[TBL] [Abstract][Full Text] [Related]
18. Adaptive designs for binary treatment responses in phase III clinical trials: controversies and progress.
Biswas A
Stat Methods Med Res; 2001 Oct; 10(5):353-64. PubMed ID: 11697227
[TBL] [Abstract][Full Text] [Related]
19. Bayesian models for subgroup analysis in clinical trials.
Jones HE; Ohlssen DI; Neuenschwander B; Racine A; Branson M
Clin Trials; 2011 Apr; 8(2):129-43. PubMed ID: 21282293
[TBL] [Abstract][Full Text] [Related]
20. Missing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthrough.
Thabut G; Crestani B; Porcher R; Richeldi L
Eur Respir J; 2015 Sep; 46(3):607-14. PubMed ID: 26324692
[No Abstract] [Full Text] [Related]
[Next] [New Search]
